Bactericidal activity in filtrated supernatant of Streptococcus sanguinis against multidrug-resistant Pseudomonas aeruginosa.
In the past decade, multidrug-resistant Pseudomonas aeruginosa (MDRP) infection has become a serious clinical problem, due to the limitation of drug choices to fight against the bacteria. Here we explored the bactericidal activity in the filtrated supernatant of Streptococcus (S.) sanguinis against Pseudomonas (P.) aeruginosa. S. sanguinis is one of the alpha-hemolytic streptococci that commonly reside in the human oral cavity. A strain of S. sanguinis, isolated from the sputum of a pulmonary-disease patient, was cultured for overnight. The filtered supernatant was tested for bactericidal effect using the minimum bactericidal concentration method on 20 strains of P. aeruginosa, including two MDRP and five mucoid-type strains. The viable number of P. aeruginosa was decreased with time after exposing to the filtrated supernatant of S. sanguinis, and collapsed bacteria were detected with electron microscopy. Of the 20 strains, 19 (95%) strains of P. aeruginosa were affected by bactericidal effect. Among other species of bacteria examined, the filtrated supernatant of S. sanguinis showed remarkable bactericidal effect on 49% of indole-positive Proteus species (4/9 strains) and 60% of Acinetobacter (A.) baumannii (6/10 strains). We next investigated the property of bactericidal activity in filtrated supernatant by treating with proteinase K or autoclave. There was no change in the bactericidal activity of the filtrated supernatant after each treatment, excluding the involvement of protein and plasmid. Here, we identify the bactericidal activity in the filtrated supernatant of S. sanguinis against MDRP. This unexpected observation may contribute to the development of a novel therapeutic drug against P. aeruginosa.
Watanabe
Kiwao
K
Department of Clinical Medicine, Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Senba
Masachika
M
Ichinose
Akitoyo
A
Yamamoto
Takeshi
T
Ariyoshi
Koya
K
Matsumoto
Keizo
K
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D015169:Colony Count, Microbial; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects*; D019286:Endopeptidase K / Q000378:metabolism; D005260:Female; D005374:Filtration; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D008875:Middle Aged; D011550:Pseudomonas aeruginosa / Q000166:cytology / Q000187:drug effects* / Q000302:isolation & purification / Q000648:ultrastructure; D013194:Staining and Labeling; D013242:Sterilization; D013291:Streptococcus / Q000737:chemistry*; D013347:Subcellular Fractions / Q000737:chemistry
D000900:Anti-Bacterial Agents; D019286:Endopeptidase K